Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 29,500 shares, a decline of 72.9% from the April 30th total of 108,900 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 441,800 shares, the days-to-cover ratio is currently 0.1 days.

Daiichi Sankyo Price Performance

Shares of OTCMKTS DSNKY traded down $0.44 during mid-day trading on Monday, reaching $26.61. The company had a trading volume of 121,705 shares, compared to its average volume of 277,258. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06. The stock has a market cap of $50.78 billion and a PE ratio of 30.94. The company has a 50-day moving average price of $24.40 and a two-hundred day moving average price of $25.93. Daiichi Sankyo has a 1-year low of $20.92 and a 1-year high of $42.48.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported $0.30 earnings per share (EPS) for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. The business had revenue of $3.40 billion for the quarter. On average, equities analysts anticipate that Daiichi Sankyo will post 0.73 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.